Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation

Set Alert for Legislation

Latest From Legislation

US House Drug Pricing Bill Amended To Target Launch Prices, Set For Swift Advance

House Speaker Pelosi’s amended HR 3 expands scope of targeted drugs, adds manufacturer transparency requirements ahead of dual markups and a hearing on 17 October.

Pricing Debate Legislation

UK Bill To Speed Up Post-Brexit Access To Innovative Drugs

A new bill giving the UK regulator more powers after Brexit has been welcomed by the life sciences industry. However, observers have warned that it needs fleshing out with detail, and that the government would be wise to proceed carefully if it considers relaxing clinical trial regulations.

United Kingdom Brexit

For Biopharma, There May Be Only One Race To Watch In 2020

Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.

Pricing Debate Legislation

Pelosi Rx Pricing Bill Offers Big Savings, Big Drop In Drug Development – CBO

Overall effect on health of US families stemming from increased use of drugs but decreased availability of new drugs is 'unclear,' the Congressional Budget Office concludes in its preliminary analysis of HR 3.

Pricing Debate Legislation

PhRMA Willing To Contribute To Drug ‘Affordability’ – But Mum On How Much

PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.

Pricing Debate Pricing Strategies

California's Pay-For-Delay Law May Be Harsher Than FTC Regulation, Could Face Legal Challenge

Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.

Legislation Intellectual Property
See All
UsernamePublicRestriction

Register

Advertisement